… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for … LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development at ProQR. “Now that the study is initiated we expect to dose the …
… ProQR Highlights Pipeline Expansion and Multiple Upcoming … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “We look forward to the target engagement data with …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… ProQR Announces Amendment to Convertible Debt Financing … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the … said Smital Shah, Chief Business and Financial Officer of ProQR. “If fully drawn down, this facility extends our cash …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
… ProQR Strengthens Scientific Advisory Board with Leaders in … said Daniel A. de Boer, Chief Executive Officer of ProQR. “These individuals bring important scientific, … for patients living with Inherited Retinal Diseases.” ProQR’s SAB is comprised of: James Shannon, MD , Chair of the …
… ProQR to Host Virtual Investor and Analyst Event Highlighting … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … in the first half of 2026, the Company will showcase ProQR’s broader RNA editing pipeline at this event, announce …